Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib, Adebrelimab, and GEMOX in Advanced Intrahepatic Cholangiocarcinoma
NCT06925516Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Apr 2025
- Primary completion
- Jun 2027
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib, adebrelimab in intrahepatic cholangiocarcinoma (ICC), sponsored by Sun Yat-sen Memorial Hospital. Started Apr 2025; status: recruiting.
02
Drugs
Rivoceranibadebrelimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06925516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06925516.